Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder

Cheryl S. Hankin, Lorrin M. Koran, Amy Bronstone, Donald W. Black, David V. Sheehan, Eric Hollander, Jeffrey D. Dunn, Larry Culpepper, John Knispel, Darin D. Dougherty, Zhaohui Wang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To determine the adequacy of pharmacotherapy received by patients with newly-diagnosed obsessive-compulsive disorder (OCD), based on current practice guidelines. Methods: A 9 year (1997-2006) retrospective claims analysis of adults enrolled in Florida Medicaid for at least 3 continuous years was conducted to determine the percentage who received both a minimally effective duration (≥ 8 continuous weeks) and dose of first-line OCD pharmacotherapy during the year following their first ("index") OCD diagnosis. Results: Among 2,960,421 adult (≥ 18 years of age) enrollees, 2,921 (0.1%) were diagnosed with OCD. Among the 2,825 OCD patients without comorbid Asperger syndrome or autism, 843 had newly-diagnosed OCD and at least 12 months of follow-up data after their index diagnosis. Among these 843 patients, 588 (69.7%) received first-line OCD pharmacotherapy but only 323 (38.3%) received a minimally effective pharmacotherapy trial in the year following their index diagnosis. Conclusions: Among clinically-diagnosed persons with OCD (<10% of those with the disorder), a minority of newly-diagnosed patients receive a minimally effective pharmacotherapy trial consistent with current standards of care. Reasons such as limited patient adherence and/or physician awareness of guidelines must be identified and redressed to ameliorate the patient, healthcare system, and economic burdens associated with OCD.

Original languageEnglish (US)
Pages (from-to)695-703
Number of pages9
JournalCNS Spectrums
Volume14
Issue number12
StatePublished - Dec 2009

Fingerprint

Obsessive-Compulsive Disorder
Medicaid
Drug Therapy
Insurance Claim Review
Asperger Syndrome
Standard of Care
Patient Compliance
Autistic Disorder
Practice Guidelines
Economics
Guidelines
Delivery of Health Care
Physicians

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Hankin, C. S., Koran, L. M., Bronstone, A., Black, D. W., Sheehan, D. V., Hollander, E., ... Wang, Z. (2009). Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. CNS Spectrums, 14(12), 695-703.

Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. / Hankin, Cheryl S.; Koran, Lorrin M.; Bronstone, Amy; Black, Donald W.; Sheehan, David V.; Hollander, Eric; Dunn, Jeffrey D.; Culpepper, Larry; Knispel, John; Dougherty, Darin D.; Wang, Zhaohui.

In: CNS Spectrums, Vol. 14, No. 12, 12.2009, p. 695-703.

Research output: Contribution to journalArticle

Hankin, CS, Koran, LM, Bronstone, A, Black, DW, Sheehan, DV, Hollander, E, Dunn, JD, Culpepper, L, Knispel, J, Dougherty, DD & Wang, Z 2009, 'Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder', CNS Spectrums, vol. 14, no. 12, pp. 695-703.
Hankin, Cheryl S. ; Koran, Lorrin M. ; Bronstone, Amy ; Black, Donald W. ; Sheehan, David V. ; Hollander, Eric ; Dunn, Jeffrey D. ; Culpepper, Larry ; Knispel, John ; Dougherty, Darin D. ; Wang, Zhaohui. / Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. In: CNS Spectrums. 2009 ; Vol. 14, No. 12. pp. 695-703.
@article{1471e1dd074d47838ea4810132e9303b,
title = "Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder",
abstract = "Objective: To determine the adequacy of pharmacotherapy received by patients with newly-diagnosed obsessive-compulsive disorder (OCD), based on current practice guidelines. Methods: A 9 year (1997-2006) retrospective claims analysis of adults enrolled in Florida Medicaid for at least 3 continuous years was conducted to determine the percentage who received both a minimally effective duration (≥ 8 continuous weeks) and dose of first-line OCD pharmacotherapy during the year following their first ({"}index{"}) OCD diagnosis. Results: Among 2,960,421 adult (≥ 18 years of age) enrollees, 2,921 (0.1{\%}) were diagnosed with OCD. Among the 2,825 OCD patients without comorbid Asperger syndrome or autism, 843 had newly-diagnosed OCD and at least 12 months of follow-up data after their index diagnosis. Among these 843 patients, 588 (69.7{\%}) received first-line OCD pharmacotherapy but only 323 (38.3{\%}) received a minimally effective pharmacotherapy trial in the year following their index diagnosis. Conclusions: Among clinically-diagnosed persons with OCD (<10{\%} of those with the disorder), a minority of newly-diagnosed patients receive a minimally effective pharmacotherapy trial consistent with current standards of care. Reasons such as limited patient adherence and/or physician awareness of guidelines must be identified and redressed to ameliorate the patient, healthcare system, and economic burdens associated with OCD.",
author = "Hankin, {Cheryl S.} and Koran, {Lorrin M.} and Amy Bronstone and Black, {Donald W.} and Sheehan, {David V.} and Eric Hollander and Dunn, {Jeffrey D.} and Larry Culpepper and John Knispel and Dougherty, {Darin D.} and Zhaohui Wang",
year = "2009",
month = "12",
language = "English (US)",
volume = "14",
pages = "695--703",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "12",

}

TY - JOUR

T1 - Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder

AU - Hankin, Cheryl S.

AU - Koran, Lorrin M.

AU - Bronstone, Amy

AU - Black, Donald W.

AU - Sheehan, David V.

AU - Hollander, Eric

AU - Dunn, Jeffrey D.

AU - Culpepper, Larry

AU - Knispel, John

AU - Dougherty, Darin D.

AU - Wang, Zhaohui

PY - 2009/12

Y1 - 2009/12

N2 - Objective: To determine the adequacy of pharmacotherapy received by patients with newly-diagnosed obsessive-compulsive disorder (OCD), based on current practice guidelines. Methods: A 9 year (1997-2006) retrospective claims analysis of adults enrolled in Florida Medicaid for at least 3 continuous years was conducted to determine the percentage who received both a minimally effective duration (≥ 8 continuous weeks) and dose of first-line OCD pharmacotherapy during the year following their first ("index") OCD diagnosis. Results: Among 2,960,421 adult (≥ 18 years of age) enrollees, 2,921 (0.1%) were diagnosed with OCD. Among the 2,825 OCD patients without comorbid Asperger syndrome or autism, 843 had newly-diagnosed OCD and at least 12 months of follow-up data after their index diagnosis. Among these 843 patients, 588 (69.7%) received first-line OCD pharmacotherapy but only 323 (38.3%) received a minimally effective pharmacotherapy trial in the year following their index diagnosis. Conclusions: Among clinically-diagnosed persons with OCD (<10% of those with the disorder), a minority of newly-diagnosed patients receive a minimally effective pharmacotherapy trial consistent with current standards of care. Reasons such as limited patient adherence and/or physician awareness of guidelines must be identified and redressed to ameliorate the patient, healthcare system, and economic burdens associated with OCD.

AB - Objective: To determine the adequacy of pharmacotherapy received by patients with newly-diagnosed obsessive-compulsive disorder (OCD), based on current practice guidelines. Methods: A 9 year (1997-2006) retrospective claims analysis of adults enrolled in Florida Medicaid for at least 3 continuous years was conducted to determine the percentage who received both a minimally effective duration (≥ 8 continuous weeks) and dose of first-line OCD pharmacotherapy during the year following their first ("index") OCD diagnosis. Results: Among 2,960,421 adult (≥ 18 years of age) enrollees, 2,921 (0.1%) were diagnosed with OCD. Among the 2,825 OCD patients without comorbid Asperger syndrome or autism, 843 had newly-diagnosed OCD and at least 12 months of follow-up data after their index diagnosis. Among these 843 patients, 588 (69.7%) received first-line OCD pharmacotherapy but only 323 (38.3%) received a minimally effective pharmacotherapy trial in the year following their index diagnosis. Conclusions: Among clinically-diagnosed persons with OCD (<10% of those with the disorder), a minority of newly-diagnosed patients receive a minimally effective pharmacotherapy trial consistent with current standards of care. Reasons such as limited patient adherence and/or physician awareness of guidelines must be identified and redressed to ameliorate the patient, healthcare system, and economic burdens associated with OCD.

UR - http://www.scopus.com/inward/record.url?scp=77749291834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749291834&partnerID=8YFLogxK

M3 - Article

C2 - 20394177

AN - SCOPUS:77749291834

VL - 14

SP - 695

EP - 703

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 12

ER -